Charm Therapeutics
Biotechnology
Lately:2 news stories in 90 daysFollow changes →
Facts
as of Nov 17, 2026Charm Therapeutics applies deep learning protein folding to drug design. Its DragonFold technology models three dimensional protein and ligand structures. The company develops its own oncology programmes.
- Headquarters
- London, United Kingdom
- Founded
- 2021
- Website
- charmtx.com
These are the key facts about Charm Therapeutics on Alion as of Nov 17, 2026. Charm Therapeutics is headquartered in London, United Kingdom. It was founded in 2021. The latest round is Series B of $80M, announced in 2025.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| London United Kingdom | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$80MTotal raised
Series BLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
Largest rounds and grants
2025
$80M
Sources: funding announcements, grant and company registers
Milestones
Sep 8, 2025
Sep 2, 2025
Raised a round Series B $80M
Sep 10, 2024
Apr 30, 2024
Mar 19, 2023
2021
Founded
Each milestone is dated by its source: registers, filings, the press
Newsroom
top 2%Web presenceof 133.2M domains by links, Common Crawl
Aug 182026
News · markets.businessinsider.com
PRESS RELEASECHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibi...
Nov 13, 20252025
Blog
AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutations First-i…
Sep 8, 20252025
Sep 2, 20252025
Jul 8, 20252025
Blog
By the CHARM Tx technology team Introduction Ligand-protein cofolding models have the potential to transform structure-based drug discovery, yet so far, they've seen limited upta…
Mar 17, 20252025
Blog
By Jan Domanski, Ph.D. Summary In small-molecule drug discovery, lead optimisation (LO) is a critical phase where promising compounds are fine-tuned for potency, selectivity, and…
Sources: the outlets named on each headline, each story once
